Clinical Trial

Phase II Study of RC1416 Injection in COPD

Name: Phase II Study of RC1416 Injection in COPD — clinical trial record (NCT07402551)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of RC1416 injection in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Protocol Amendment History 1 change

critical Recruitment opened 2026-04-18

Trial Details

NCT Number	NCT07402551
Lead Sponsor	Nanjing RegeneCore Biotech Co., Ltd.
Conditions	Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Enrollment	180 participants
Start Date	2026-03-06
Primary Completion	2028-05-31 (estimated)
Study Completion	2028-08-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-09